Introduction
Desirability functions have enjoyed sustaining popularity in the industrial sector but their use in the medical sciences has been rather limited to date. Their origin and use were motivated by the need to use several outcome measures to evaluate the overall quality of a product using a single score. Each component of the composite measure is given a desirability score and the overall desirability score is obtained by combining the individual scores from all components in the composite measure. High scores represent better quality and they are conveniently scaled between 0 and 1, with 1 representing the best possible product. Desirability function was first There is only a handful of papers on use of desirability functions for biomedical studies. Shih et al. [22] used desirability functions to titrate and evaluate multi-drug regimens within subjects using a modified evolutionary operation approach and climbed through the dose space to locate dose that patient had an improved response. They used a logistic cumulative distribution function for specifying the desirability function and then combined desirability functions using the geometric mean. Wong et al. [24] used the median of measures in selected groups of patients to construct the desirability function for monitoring scleroderma patients' disease progression when outcomes are all continuous. Design problems were also addressed using the desirability function; see [17] , where they provided yet another innovative application of the desirability function to design dose response studies for nonlinear models. Additionally, Fransen et al. [7] used the medians of 44 expert-rheumatologists' ratings of patients with psoriatic arthritis (PsA) to develop a desirability function for each component measure and combine the desirability scores using the L p norm. Recently, Helliwell et al. [12] developed a composite measure for PsA using the Ankylosing Spondylitis DAS and the desirability function suggested by Fransen et al. [7] . After establishing the desirability function cutoffs for disease activity using an online survey technique, these individual functions were then combined into a single measure using the arithmetic mean.
Some key issues in applying desirability functions for medical studies is the availability of a 'gold' standard, the accuracy of each of the constructed desirability functions and the overall desirability function. The shape of the desirability function provides information on how the outcome or its change is interpreted or valued relative to the chosen gold standard, which for clinical applications, is typically some global assessment standard established by an expert pool of physicians. In the above cited work, the desirability function was constructed in an empirical way to reflect consensus from a group of experts and assumed data were available at two time points. Further, when outcomes were perceived to have differential effects on the overall disease progression, the weighted desirability function had weights a priori selected. This suggests that the desirability function constructed in such an empirical way can be problematic in a number of ways: (i) the physicians or experts may not come to a general agreement on what amount of change in the outcome corresponding to what degree of disease progression; (ii) the pool of physicians selected to establish the gold standard and interpretation may be subject to selection bias; (iii) there is no systematic way to select the weight for each outcome even though their perceived importance and usefulness for measuring disease progression may be deduced from literature review, see, for example, [18] .
In what is to follow, we propose a data-driven approach to estimate all desirability functions for the various outcomes based on a given gold standard. Specifically, we provide a method to estimate the shape of each desirability function and an appropriate set of weights for the overall desirability function. The advantages of a data-driven approach are that our estimated shapes and weights in the desirability function incorporate cohort characteristics and should reflect disease progression more accurately. In addition, we propose a new approach to using desirability functions with longitudinal data for a more insightful picture of the patient's progress over time relative to the cohort.
The next section describes clinical outcome measures used for assessment of Scleroderma progression in a two-arm randomized trial conducted by Postlewaite et al. [19] . Section 3 first gives an overview on the construction of the desirability function and its properties. We then demonstrate our proposed data-driven approach for estimating desirability function shapes and weights and extend the methodology in a novel way to monitor patients' disease progression when there are multiple time points. In Section 4, we apply our proposed method to the real data of Scleroderma. Section 5 offers a discussion. Downloaded by [Hsiu-Wen Chen] at 05:31 23 November 2015
Scleroderma data
Scleroderma is an inflammatory rheumatic disease with multiple disease outcomes. Scleroderma usually affects a large area of skin, lungs, and other internal organs of the patient. We have data from a multicenter, randomized, double-blind, placebo-controlled trial for 168 Scleroderma patients treated with oral type I collagen or placebo. The treatments were administered over a 12-month period with a follow up visit at month 15. Details and results of the trial can be found in [19] . Following Wong et al. [24] and Postlethwaite et al. [19] , five continuous outcome measures are used to evaluate diffuse scleroderma disease progression, including the modified Rodnan total skin score (SKINTOT), the disability index of the health assessment questionnaire (HAQ), the predicted values of the forced vital capacity (FVCP), the patient's global assessments of health (PGA), and the physician overall assessment of disease activity (POA).
Typically, SKINTOT and HAQ are considered to be the most important and serve as two primary outcomes in a Scleroderma clinical trial [19] . SKINTOT is quantitative by assessing 17 body areas with each area receiving a 0-3 score with 0 = normal; 1 = mild thickness; 2 = moderate thickness; 3 = severe thickness, and summing over all the areas. HAQ is a selfreported patient-oriented measure and has four scoring conventions for the disability index questions on a scale of 0-3 with 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. FVCP is calculated from patient's characteristics and is more fully described in [24] . It takes on positive values with no upper bound. The last two outcome measures are PGA and POA and both aim to track disease progression as judged by the patient alone or by the physician alone. Either one of these may be treated as a gold standard for assessing disease progression in Scleroderma patients in a clinical trial. Both are rated using Visual Analogue Scales on 0-100 mm varying from no activity to extremely high activity.
In this data, we have SKINTOT at months 0, 4, 8, 12, and 15. The maximum score for this measure is 51 with lower values (relative to baseline) indicative of disease progression. We have HAQ data at months 0, 4, 8, 12, and 15 and a lower value of HAQ is suggestive of functional progression. A higher value of FVCP is suggestive that lung functions in the patient are performing better. Such data is expensive to collect and we only have data at months 0 and 12. Both PGA and POA are available at months 0, 4, 8, 12, and 15 in the trial and a lower value is better.
Following Postlethwaite et al. [19] , the change score for each outcome from baseline to month 12 is used to measure disease activity, calculated by subtracting the score at baseline from the score at the12-month visit. This choice of using the raw difference is the simplest way, and other options of defining change in outcomes are possible. In this trial, Postlethwaite et al. [19] showed that oral type I collagen treatment was no more effective than placebo. Accordingly, we combined placebo and treatment groups for measuring patients' disease progression in this study.
Methods

Desirability function
The desirability function was first used in the manufacturing sector to combine multiple continuous outcomes into one numeric score as an overall assessment of the quality of the product [10] . Assuming all responses are independent, this approach first creates an individual desirability function d i to map the ith outcome value y i to a scalar between 0 and 1, where a higher value of d i represents greater desirability. This transformation has to be meaningful and make sense in the context of the problem. For instance, if large values of outcome are more desirable, the transformation d i should be a monotonic increasing function of y i .
Harrington [10] Harrington's transformations and classified them into three forms: the smaller-the-better (STB), the larger-the-better (LTB), and the nominal-the-best (NTB) types. For the STB type, it is desirable to have the outcome value as small as possible. There is a lower bound L i and an upper bound U i for the ith outcome y i such that it is unacceptable when y i > U i and described as perfect or most desirable when y i < L i . Such a desirability function is defined by
where r i > 0 is the shape parameter and, like L i and U i , is user-selected. [5] . The individual desirability scores d i s from the various components are then combined into one overall desirability score using the geometric mean
1/m , where m is the number of outcomes [10] . The value of D is between 0 and 1. The higher the value of D, the more desirable is the overall product. Clearly, high values of the d i s result in a high value of D. If all the outcomes are not equally important, a weighted desirability function may be used to reflect the varying contribution from each outcome to the overall desirability score as follows:
The weights satisfy w i > 0 with more important outcomes having larger weights [4] . The D or D w function has the property that if one characteristic or response is totally unacceptable (d i = 0), then the overall product or process receives a desirability score D = 0. This assumes that the particular component measure is extremely important because it can solely decide on the overall score. Such a property may or may not be desirable but whether or not to assign a component score equal to zero has to be carefully weighed in. Alternatively, one can define the overall desirability D as the arithmetic mean or weighted averages of the d i s with or without some penalty function; see [14] [15] [16] . Fransen et al. [7] recommended the L p norm to combine desirability scores in a flexible way after a careful choice of the value for p. This norm is defined by
and L −∞ correspond, respectively, to the geometric mean, arithmetic mean, maximum, and minimum. For example, we note that when p = 0,
and applying the L'Hôpital's rule, one obtains 
Proposed methods
Data-driven approach
Estimate of the desirability function shape. This parameter is important because different values of this shape parameter signify the degrees of importance of the various amounts of change. For example, a relatively flat desirability function suggests that a relatively large amount of change in the outcome will be required to impress physicians that there is real progression in the patient based on the particular outcome. Physicians however may have their own preferences for the value of the shape parameter and there may not be a consensus on an appropriate value for the shape parameter to use in the study. One way to tackle this issue is to use a data-driven approach to estimate the desirability function shape. For illustrative purposes, consider that the ith variable has the STB type of desirability function as an example. Given the lower and upper bounds L i and U i , the desirability func-
Suppose that d g is the given gold standard and rescaled to vary from 0 to 1. In the data-driven approach, we want d i to approximate d g as closely as possible. A simple model is
where ε i is the approximation error. This is a nonlinear regression problem and we use nonlinear least squares method to estimate the shape parameter r i . The same procedure can be directly applied to estimate desirability function shapes for the LTB and NTB types when a target value is available. Once the desirability function shape r i for each outcome is obtained from the datadriven approach and the given gold standard, the desirability score d i for each outcome can be determined.
Estimate of the desirability function weights. The data-driven approach can be employed to find suitable weights for various outcomes as follows. Given individual desirability scores, d 1 , . . . , d m , from various components, in order to approximate the rescaled gold standard d g with D w in (1), we consider the following model
We can fix one of the weights, say w 1 = 1, in Equation (3) and use nonlinear least squares method to estimate the other weights w i . The choice for which one of the weights to drop is arbitrary as it does not affect the results. We can always rescale the weights to make m i=1 w i = 1 after the estimation. The estimated weights allow us to compute the value of the overall desirability score D w in Equation (1). Our experience is that the estimated weights from biomedical data are usually positive. If necessary, we can use constrained nonlinear least squares to ensure that all estimated weights are non-negative.
Analyzing longitudinal data
For each time point, let d it be the desirability score for change in each outcome y i at time t. We define an overall desirability score at time t by D t = (d 
where λ j is the weight of time point t j and j = 1, . . . , k.
Application
We apply our proposed methods to the real data of Scleroderma for monitoring disease progression of patients over time. For illustrative purposes, we first monitor patients' disease progression with data at baseline and at month 12 for each outcome. The reason for considering two time points is that SKINTOT and HAQ are available at months 0, 4, 8, 12, and 15 in the trial, but FVCP is only available at months 0 and 12. The desired type and measures of change in each outcome are given in Table 1 . In this study, a negative change implies disease progression in SKINTOT (y 1 ), HAQ (y 2 ), PGA (y 4 ), and POA (y 5 ) while a positive change implies progression in FVCP (y 3 ). Following current practice in Scleroderma trials, we select change in one of the outcomes PGA and POA as our gold standard as a reference for mapping changes in other outcomes SKINTOT, HAQ, and FVCP into desirability scores. The bounds L i and U i for change in each outcome are chosen based on their observed ranges from baseline to month 12. The first step is to rescale changes in PGA and POA to values between 0 and 1 using the desirability function. In this study, we do not have these desirability functions from experts. For illustrative purposes, we assume r 4 = r 5 = 1 in the following analyses. For each patient, we obtain the values of d 4 and d 5 for changes in PGA and POA from baseline to one year. Based on the rescaled scores d 4 and d 5 , we estimate the desirability function shapes for changes in SKINTOT, HAQ, and FVCP using the data-driven approach. Using PGA as the gold standard, we obtainr 1 = 0.68 with the 95% confidence interval (0.6, 0.76) listed in Table 1 . Similar calculations are applied to each outcome when POA is chosen as the gold standard. The robustness to extreme outcomes was evaluated and no major changes were observed. Table 1 also shows that the upper limits of the 95% confidence intervals for estimated desirability function shapes for changes in SKINTOT, HAQ, and FVCP using the gold standard PGA are smaller than 1, but their lower confidence limits for changes in HAQ and FVCP using the Table 1 . Desired type and estimate of the desirability function shape and weight for change in each outcome from baseline to one year using r 4 = r 5 = 1. gold standard POA are larger than 1. This implies that the gold standard PGA tends to provide smaller estimates of desirability function shapes. We next estimate weights for SKINTOT, HAQ, and FVCP using the data-driven approach. The estimated weights for SKINTOT, HAQ, and FVCP, shown in Table 1 , are respectively 0.45, 0.42, and 0.13 when PGA is used as the gold standard, and 0.13, 0.68, and 0.18 when POA is used. Under PGA scale, change in SKINTOT receives the highest weight and is deemed the most important. When POA is used, the corresponding change in HAQ has the largest weight suggesting that HAQ contributes the most to the overall score. Clearly, patients perceive progression in SKINTOT as the major contributing factor to overall disease progression among the various measures considered while the physicians place greatest emphasis on HAQ as the major contributing factor to disease progression. This suggests that PGA and POA may be intrinsically different constructs when they are used to interpret disease progression. The finding here gives support that physicians and patients may have different perception of disease progression. Figure 1 shows that the estimated data-driven desirability functions for change in SKINTOT, HAQ, and FVCP from baseline to one year with r 4 = r 5 = 1. We observe that PGA and POA have different appreciations of an increase in change in the three outcomes. Specifically, if PGA is used as the gold standard, we have higher desirability scores for SKINTOT, HAQ, and FVCP. This means that using PGA as the gold standard, a small change or no change in the three Downloaded by [Hsiu-Wen Chen] at 05:31 23 November 2015 outcomes is deemed as more indicative of some progression than if POA is used as the gold standard. More specifically, Figure 1 suggests that no change in any one of the three outcomes would each receive a desirability score of about 0.4 to 0.5 when POA is used as the gold standard versus a desirability score of about 0.6 if PGA is used as the gold standard. These scores translate to a rating of 'acceptable but poor' interpretation according to Harrington's guidelines [10] . The upshot is that while the values for the desirability scores are different from different gold standards, the qualitative interpretation of disease progression is similar. Next, for illustrative purposes, we drop FVCP and work with only SKINTOT and HAQ from multiple visits. Table 2 shows their estimated desirability function shapes and corresponding 95% confidence intervals, as well as their estimated weights over time. At month 4, the estimates of shape are all larger than 1 and are similar using either PGA or POA as the gold standard. At months 8, 12, and 15, the estimates of shape under PGA scale are smaller than the estimates under POA scale. This implies that patients and physicians had similar views in disease progression at month 4 but their views diverged over time. The patients appeared to be more positive than the physicians at months 12 and 15. In addition, we observe that larger weights are obtained for SKINTOT under PGA and smaller weights are obtained for SKINTOT under POA at each time point. Table 3 shows the changes and estimated data-driven desirability scores in SKINTOT and HAQ from baseline to each time point for the patient with id = 16. With p = 1 and equal weights, the patient has a composite overall score of D* = (0.47 + 0.51 + 0.65 + 0.85)/4 = 0.62 under PGA. In practice, current drug treatments for Scleroderma are slow acting and not expected to have an effect on the patient until about four or more months later. This means that change measurements from patients at four months or earlier should receive small weights. Measurements after six months should receive larger weights increasingly for change measurements collected over a longer period of time. For this reason, it seems more appropriate to assign increasing weights such as (λ 1 , λ 2 , λ 3 , λ 4 ) = (1, 2, 4, 8 desirability scores. First, we illustrate that the score of D* does not change greatly after having a low score at an early time point. Suppose month 4 had D t1 = 0.1 (instead of 0.47) under PGA, the score of D* would be 0.70. That is, a score near 0 at the beginning will not affect the final result too much. Second, we illustrate how to deal with missing values without imputation in practice. Suppose that data at month 8 are missing under PGA and we only have the scores at months 4, 12, and 15 for this patient. We can simply set the weight λ 2 = 0 for month 8 and keep the weights for other time points. Then the composite overall score can be computed as
The desirability scores can be used in analyzing longitudinal data. For illustration, we consider using the desirability scores to test whether the collagen and placebo groups were significantly different. Table 4 shows the means and standard deviations of the desirability scores for two groups, t statistics and p-values at each time point, as well as the measures of the composite overall desirability D* using p = 1 and weights (λ 1 , λ 2 , λ 3 , λ 4 ) = (1, 2, 4, 8) . The large p-values indicate no difference between collagen and placebo groups at each time point or across all time points. This reaffirms the conclusions from [19] that the collagen group did not fare significant better over the placebo group over time.
Discussion
Measuring patients' disease progression with multiple outcomes is increasingly common, but challenges arise when we try to combine all these outcomes into a single meaningful progression Downloaded by [Hsiu-Wen Chen] at 05:31 23 November 2015 score that incorporates multiple outcome measures appropriately. We propose the data-driven approach to construct desirability functions that can potentially highlight selection bias and subjective judgments. Specifically, unlike previous approaches, we estimate the shapes of the desirability functions and also the weights for all outcomes based on the given gold standard and the observed data. The upshot is that each patient has a meaningful overall progression score that facilitates clinical interpretation. In addition, we show how additional information from a longitudinal study can be integrated into the single desirability score in a novel way for a more insightful picture of patients' progress over time.
A salient finding from our analyses is that our estimates of shapes and weights of the desirability functions depend on the choice of the gold standard. When PGA is used as the gold standard, we always have a larger desirability score for the yearly change in SKINTOT, HAQ, and FVCP than if we use POA as the gold standard. Even if the values for the desirability scores are different from different gold standards, their qualitative interpretation of disease progression is similar in this study. Overall, we find that scleroderma patients in this trial do not show a significant progression over time.
The use of the geometric mean to combine the various desirability scores means that the overall desirability score is 0 as soon as one of the sub scores is 0. An alternative way may use the arithmetic mean, where poor scores on one component can be compensated by good scores on another component. Our proposed method with the modified L p norm for analyzing longitudinal data works when a patient has a desirability score near 0 at the beginning of the trial but then markedly improves. Poor scores at early time points can be compensated by good scores at later time points in D*. However, for the multiplicative approach, this compensation is only possible on relatively high scores at most time points. As scores at some time points become lower, it is more difficult to compensate at all and usually result in a poor composite score.
Missing data are common in clinical trials. In this study, we work with patients with complete data only. We further conduct multiple imputations using package (mice) in R to generate 10 complete data sets. The p values for testing collagen and placebo groups are all above 0.30 using the composite overall desirability scores, which is consistent with Table 4 . In practice, there is a need for a doctor to deal with missing data for an individual patient without multiple imputation. With our proposed method for analyzing longitudinal data, a doctor can simply use the available data by setting λ j = 0 if the outcomes at time t j are missing in D*.
In longitudinal analysis, weights may be chosen proportional to the distance between baseline and at user-selected time point, with larger weights for longer distances. This is particularly appropriate for rheumatic diseases where the treatment is usually slow-acting, meaning that effects of the drug will not manifest themselves until a few months later or after the accumulated doses in the patient exceeds some threshold. However, we do not incorporate the correlation in the desirability scores across time in our proposed method for analyzing longitudinal data.
In this study, we do not have information to derive the desirability functions and weights from a panel of experts. Our estimated data-driven shapes and weights of the desirability functions depend on rescaled PGA and POA, which are based on r 4 = r 5 = 1. The values of r 4 and r 5 are chosen in an empirical way in this study. Accordingly, we compare the results under PGA and POA scales.
In summary, our work appears to be the first to discuss desirability function and its potential use in longitudinal studies. Our work provides two innovations for the use of desirability functions. First, we used a data-driven approach to estimate the desirability function and second, we are the first to apply in a novel way how desirability functions can be used in the analysis of longitudinal data. The method is relatively simple and so may appeal to researchers who want more insight how different component measures affect the overall disease progression of the patients. Our method also incorporate missing data in a simple way but more sophisticated methods can be used. For example, one may wish to incorporate correlations among the multiple outcomes in Downloaded by [Hsiu-Wen Chen] at 05:31 23 November 2015 ways similar to recent ideas proposed in the literature [25, 21] . Our application was for rheumatic diseases but the method is general and can be used to broadly analyze other longitudinal studies as well. Of course, we do not suggest that this approach supplants conventional statistical methods for longitudinal analyses but use the desirability approach as an alternative and simple method to possibly gain insights beyond those obtained from standard statistical analyses.
